Resultado de búsqueda
The Elista Children's Hospital faces the USSR's first major HIV outbreak in the 1980s, with over 70 children and adults infected. Doctors, patients, and families strive to uphold dignity amidst an incurable disease.
OPDIVO is a proven immunotherapy to help your body fight against cancer. Alone or in combination with other therapies, OPDIVO is approved by the FDA to be a first treatment option for many types of cancer. Talk to your healthcare provider to find out if OPDIVO or an OPDIVO‑based combination is right for you.
USSR, 1980s. The Elista Children's Hospital is experiencing the country's first major HIV outbreak, with more than 70 children and several adults infected. Now everyone - doctors, patients, relatives - needs to preserve human dignity in the face of a terrible disease for which there is no cure yet.
2 de oct. de 2020 · Today, the FDA approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adults with malignant pleural mesothelioma that cannot be removed by surgery.
12 de nov. de 2020 · The FDA approved nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.
31 de may. de 2022 · On May 27, 2022, the Food and Drug Administration approved the following for the first-line treatment of patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC):
19 de may. de 2021 · Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma. Data evaluating Opdivo plus Yervoy represent the longest reported median overall survival from a Phase 3 advanced melanoma trial.
